Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer
NCT06696768Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emavusertib in colorectal cancer (CRC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose limiting toxicities and Incidence of treatment-emergent adverse events. Started Jun 2025; status: recruiting.
02
Drugs
emavusertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06696768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696768.